Tailoring Ibrutinib Doses in CLL: Why One Size Doesn’t Fit All

A new real-world study sheds important light on how decisions to reduce, pause, or switch from treatment with ibrutinib for chronic lymphocytic leukemia (CLL) play out and what they mean for patient outcomes. Published in Cancers (Basel), authors explain that adverse effects (AEs) of ibrutinib, such as atrial fibrillation, high blood pressure, and other cardiovascular complications, can make it difficult for some patients to stay on the standard dose of 420 mg per day.¹

Using data from the EVIdeNCE study (NCT03720561), they conducted a post hoc analysis of a prospective, multicenter observational study that tracked 275 patients with CLL receiving ibrutinib across 39 Italian hematology centers. The patients received ibrutinib in either the first line (37%) or a subsequent line (63%). Patients were followed for up to 24 months, with treatment information recorded from medical records at regular intervals.

The primary outcome of interest was relative dose intensity (RDI), or how much of the prescribed dose a patient actually received over time. RDI was calculated at 30, 60, and 90 days after starting treatment, with a score of 100% indicating a patient received the full dose every day during that window. Researchers then examined whether RDI levels were linked to differences in progression-free survival (PFS) or overall survival (OS).

Who Started at a Lower Dose—and Why

Overall, 82% of the 275 patients began ibrutinib at the standard full dose of 420 mg per day. The remaining 17.8% (n = 49) started at a reduced dose: either 280 mg (9.5%; n = 26) or 140 mg (8.4%; n = 23) daily. Physician preference was the most common reason for a lower starting dose, as seen for 75.5% (n = 37) of this group, followed by comorbidities or worsening preexisting health conditions (14.3%; n = 7) and concerns about concomitant medications (8.2%; n = 4).

Patients who started at a reduced dose tended to have more health complications overall, reflected in higher median scores on the Cumulative Illness Rating Scale (CIRS) vs the full-dose cohort: 5 (range, 2-7) vs 3 (range, 1-6; P = .022). They also had worse functional status as measured by Eastern Cooperative Oncology Group Performance Status (P < .001) and were older, with a median (IQR) age of 72 years (68-79) vs 71 years (65-77).

The presence of cardiovascular disease, a top-cited concern around ibrutinib use, was not significantly different between those who started on a full dose vs those who started on a lower dose. This finding is meaningful, the authors highlight, because it suggests that having a heart condition does not, on its own, determine the dose a patient receives.²

What Happened to RDI Over Time

Among patients who started on the full dose, the proportion maintaining 100% RDI declined modestly over the first 90 days: from 73.8% at 30 days to 65.7% at 90 days.¹ Approximately 79% of patients maintained at least 80% of their intended dose by the 90-day mark, suggesting that most patients tolerated the therapy reasonably well during the critical early treatment period. Within the first 90 days, around 9% of patients who started on the full dose required at least 1 dose reduction, most often driven by toxicity. Temporary treatment interruptions, lasting less than 3 months, occurred in 14.9% of the overall group, accounting for 43 episodes.

In initial unadjusted analyses, patients who maintained 100% RDI at 90 days showed better PFS, but the association did not remain after considering comorbidity burden, cardiovascular history, and functional status. The patients who needed dose reductions were sicker to begin with, the authors explained, so that when those underlying differences were factored in, dose reductions did not independently worsen survival. The same pattern held when looking at OS.

Maintaining full-dose RDI at 90 days appeared more important for patients with high-risk disease features, such as TP53 mutations or advanced-stage disease, the authors added.

What These Findings Mean for Patients

These findings reinforce an important principle in modern CLL care: treatment should be tailored to the individual. Each patient’s overall health, functional ability, and tolerance for AEs should guide dosing decisions, not disease biology alone. Reducing the dose for patients who struggle with AEs appears to be a safe and reasonable strategy that does not compromise ibrutinib’s effectiveness. Further, cardiovascular comorbidities, when well managed, should not be treated as automatic barriers to standard ibrutinib dosing.

For patients living with CLL, this study offers reassurance. “Collectively, these results emphasize the importance of individualized management strategies that integrate both disease biology and patient comorbidity profiles to optimize therapeutic outcomes and ensure long-term treatment success in real-world CLL care,” the authors conclude.

There are several limitations to these results. The authors note that their subgroup analyses were underpowered, and RDI was only measured in the first 90 days after treatment initiation, so long-term behavior was not captured. Also, reasons for dose reduction were not always explained, and data were missing for some variables, chiefly genetic markers.

References

1. Molica S, Scalzulli PR, Scarfò L, et al. Early ibrutinib dose modifications in CLL: a post hoc analysis of the real-world EVIdeNCE study. Cancers (Basel). 2026;18(6):1000. doi:10.3390/cancers18061000
2. Shadman M, Burke JM, Cultrera J, et al. Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. Blood Adv. 2025;9(16):4100-4110. doi:10.1182/bloodadvances.2024015493